CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 53 enrolled
Drug / intervention
Docetaxel +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03879577
NCT03879577Phase 2Active
CompareCT.gov

Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)

University of Chicago·interventional·Posted Mar 19, 2019·Updated Jan 21, 2026

In Brief

A Phase 2 clinical trial evaluating Docetaxel, Herceptin, and 4 other interventions for Breast Cancer and 4 related conditions. Active but no longer recruiting, targeting 53 participants across 1 site.

Detailed Summary

This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Breast Cancer Female, HER2-positive Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
CountriesNigeria
Collaborators--

Timeline

Phase 2Active
20192020202120222023202420252026
First PostedMar 19, 2019
Enrollment StartNov 25, 2019
Primary CompletionMar 30, 2023
Study CompletionSep 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.3 years ago

Interventions

Docetaxeldrug

Administered to all patients for a minimum of 4 cycles for 12 weeks.

Herceptindrug

Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.

FECdrug

Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

Tamoxifendrug

Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Letrozoledrug

Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

LHRH agonistdrug

Administered to all premenopausal patients.